Skip to main content
. 2019 Oct 22;20:380. doi: 10.1186/s12882-019-1578-5

Table 2.

Comparison of mortality and renal outcomes between cancer and no cancer patients in both total and matched sample

Total sample Propensity matched sample
Variable Total (2952) Cancer (339) No cancer (2613) p-Value Total (674) Cancer (337) No cancer (337) p-Value
Follow-up, months 48 (25–79) 40.3 (20.5–68) 48.2 (25–79) 0.001 43 (21–75) 40.6 (21–68) 47.1 (21.6–78.5) 0.09
Age at death, years 78.7 (72–84) 79 (72.4–84.7) 78.5 (72.1–84.4) 0.88 79 (72–84) 79 (72–84) 80.5 (75–86) 0.03
All-cause mortality 1084 (36.7%) 168 (49.6%) 916 (35%) < 0.001 295 (43.8%) 166 (49.3%) 129 (38.3%) 0.004
Cause of death (cancer) 74/474 (15.6%) 20/76 (26.3%) 54/398 (13.5%) 0.005 26/128 (20.3%) 20/76 (26.3%) 6/52 (11.5%) 0.04
Cause of death (CVD) 154/474 (32.5%) 20/76 (26.3%) 134/398 (33.7%) 0.21 33/128 (25.7%) 20/76 (26.3%) 13/52 (25%) 0.87
Cause of death (infection) 124/474 (26.1%) 16/76 (21%) 108/398 (27.1%) 0.27 30/128 (23.4%) 16/76 (21%) 14/52 (27%) 0.44
NFCVE 282 (9.55%) 30 (8.9%) 252 (9.6%) 0.64 52 (7.71%) 30 (8.9%) 22 (6.5%) 0.25
ESRD (RRT+ eGFR <or = 10) 855 (29.9%) 87 (25.7%) 768 (29.4%) 0.16 174 (25.8%) 87 (25.8%) 87 (25.8%) 1.00
CC 233 (7.9%) 29 (8.6%) 204 (7.8%) 0.18 51 (7.6%) 29 (8.6%) 22 (6.5%) 0.24
RRT 622 (21%) 58 (17.1%) 564 (21.6%) 0.06 123 (18.25%) 58 (17.2%) 65 (19.3%) 0.49
First start RRT modality (TX) 97/622 (15.5%) 3/58 (5.17%) 94/564 (16.6%) 0.02 10/123 (8.1%) 3/58 (5.2%) 7/65 (10.7%) 0.26
First start RRT modality (HD) 323/622 (51.9%) 40/58 (68.9%) 283/564 (50.2%) 0.006 78/123 (63.4%) 40/58 (68.9%) 38/65 (58.5%) 0.23
First start RRT modality (PD) 202/622 (32.5%) 15/58 (25.9%) 187/564 (33.2%) 0.26 35/123 (28.5%) 15/58 (25.8%) 20/65 (30.8%) 0.55

Cause of death represents 1a cause of death in death certificate. Cause of death available only in 474/1084 patients of the total sample (76/168 in cancer group and 398/916 in no cancer group) and 128/295 of matched sample (76/166 in cancer group and 52/129 in no cancer group). CVD-cardiovascular disease

NFCVE non-fatal cardiovascular events, ESRD end-stage renal disease, eGFR estimated glomerular filtration rate, RRT renal replacement therapy, CC conservative care, TX renal transplant, PD peritoneal dialysis, HD haemodialysis. Continuous variables are expressed as median (interquartile range) and p-Value by Man-Whitney U test

Categorical variables are expressed as number (%) and p-Value by Chi-square test. Statistically significant p-values are displayed in bold (i.e. p < 0.05)